Management of Low-risk and Intermediate-risk Non-Muscle-invasive Bladder Carcinoma
SourceHematology-Oncology Clinics of North America, 29, 2, (2015), pp. 219-225
Article / Letter to editor
Display more detailsDisplay less details
Hematology-Oncology Clinics of North America
SubjectRadboudumc 15: Urological cancers RIMLS: Radboud Institute for Molecular Life Sciences
Non-muscle-invasive bladder cancer is a highly recurrent disease. The health care costs for non-muscle-invasive bladder cancer are a major burden for society. Bladder cancer treatment starts with a presumed complete transurethral resection of a bladder tumor. Despite international guidelines for perioperative and/or adjuvant intravesical instillation therapy in non-muscle-invasive bladder cancer, adequate worldwide application is lacking. In patients who do get adjuvant intravesical instillations, recurrences are still frequent. New therapies in non-muscle-invasive bladder cancer are unsatisfactory and still experimental.
Upload full text